癌症高甲基化1在非小细胞肺癌中的表达及其临床意义

doi:10.11904/j.issn.1002-3070.2024.05.005

摘要/Abstract

摘要： 目的研究非小细胞肺癌(Non-small cell lung cancer,NSCLC)患者癌症高甲基化1(Hypermethylated in cancer 1,HIC1)表达水平与总生存期(Overall Survival,OS)之间的相关性。方法本研究从Kaplan-Meier Plotter(KM plotter)数据库中收集有详细的病理类型、临床分期和治疗信息,且具备完整的RNA-seq或基因芯片数据的患者,NSCLC共计2 166例,其中包括1 161例腺癌患者和780例鳞状细胞癌患者。利用Kaplan-Meier Plotter在线数据库进行Cox回归分析,多因素Cox回归分析校正了如下混杂因素:性别、吸烟史、临床分期、手术切缘状态、化疗和放疗情况。分析了2 166例NSCLC患者的HIC1 mRNA表达水平和OS间的关系。采用Transwell迁移实验检测敲减HIC1基因后对人肺腺癌细胞株(PC9)细胞迁移能力的影响。结果接受化疗的肺腺癌患者中,HIC1高表达显著延长了患者OS(HR=0.54,95% CI:0.34~0.86,P=0.009),死亡风险降低了46%。Transwell细胞迁移实验结果发现HIC1低表达组PC9细胞迁移能力升高(P＜0.001)。结论 HIC1 mRNA表达可能成为接受化疗的NSCLC患者重要的预后指标。

关键词: 非小细胞肺癌, 癌症高甲基化1, 总生存期

Abstract: Objective The aim of this study was to investigate the correlation between the expression of hypermethylated in cancer 1(HIC1)and overall survival(OS)in non-small cell lung cancer(NSCLC)patients. Methods A total of 2,166 patients with NSCLC,including 1 161 patients with adenocarcinoma and 780 patients with squamous cell carcinoma,were collected from the Kaplan-Meier plotter plus(KM plotter)database with detailed pathological type,clinical stage,treatment information,and complete RNA-seq or Gene chip data.Univariate Cox proportional risk regression analysis was performed using KM plotter online database.Multivariate Cox regression analysis corrected for the following confounding factors:gender,smoking history,clinical stage,surgical margin status,chemotherapy and radiotherapy.The relationship between the expression of HIC1 mRNA and OS in 2,166 NSCLC patients was analyzed.Transwell migration assay was used to detect the effect of knockdown HIC1 gene on the migration ability of PC9 cells(lung adenocarcinoma cell line). Results In lung adenocarcinoma patients receiving chemotherapy,the high expression of HIC1 significantly prolonged the OS(HR=0.54,95% CI:0.34-0.86,P=0.009),and reduced the risk of death by 46%.Transwell cell migration assay showed that the migration ability in PC9 cells in the low expression of HIC1 was increased(P＜0.001). Conclusion The expression of HIC1 mRNA may be an important prognostic predictor for NSCLC patients receiving chemotherapy.

Key words: Non-small cell lung cancer, Hypermethylated in cancer 1, Overall survival

中图分类号:

R734.2

郝慧婷, 赵惠娟, 徐巧慧. 癌症高甲基化1在非小细胞肺癌中的表达及其临床意义[J]. 实用肿瘤学杂志, 2024, 38(5): 306-312.

HAO Huiting, ZHAO Huijuan, XU Qiaohui. Expression and clinical significance of hypermethylated in cancer 1 in non-small cell lung cancer[J]. Journal of Practical Oncology, 2024, 38(5): 306-312.

参考文献

1 Siegel RL,Miller KD,Fuchs HE,et al.Cancer statistics,2022[J].CA Cancer J Clin,2022,72(1):7-33.
2 Han BF,Zheng RS,Zeng HM,et al.Cancer incidence and mortality in china,2022[J].J Natl Cancer Cent,2024,(1):47-53.
3 Herbst R,Heymach,J,Lippman S.Lung cancer[J].N Engl J Med,2008,359(13):1367-1380.
4 Wales M,Biel M,Deiry M,et al.p53 activates expression of HIC-1,a new candidate tumor suppressor gene on 17p13.3[J].Nat Med,1995,1(6):570-577.
5 Van Rechem C,Boulay G,Pinte S,et al.Differential regulation of HIC1 target genes by CtBP and NuRD,via an acetylation/SUMOylation switch,in quiescent versus proliferating cells[J].Mol Cell Biol,2010,30(16):4045-4059.
6 Chen WY,Wang DH,Yen RC,et al.Baylin,tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses[J].Cell,2005,123(3):437-448.
7 Wang X,Wang Y,Xiao G,et al.Hypermethylated in cancer 1(HIC1)suppresses non-small cell lung cancer progression by targeting interleukin-6/Stat3 pathway[J].Oncotarget,2016,7(21):30350-30364.
8 Zhou XG,Zhang P,Hu H,et al.Hypermethylated in cancer 1(HIC1)suppresses bladder cancer progression by targeting yes-associated protein(YAP)pathway[J].J Cell Biochem,2019,120(4):6471-6481.
9 Yinli Z,Leyan L,Haipeng C,et al.Luteolin exhibits synergistic therapeutic efficacy with erastin to induce ferroptosis in colon cancer cells through the HIC1-mediated inhibition of GPX4 expression[J].Free Radic Biol Med,2023,1:208:530-544.
10 Carter M,Johns M,Zeng X,et al.Mice deficient in the candidate tumor suppressor gene Hic1 exhibit developmental defects of structures affected in the Miller-Dieker syndrome[J].Hum Mol Genet,2000,9(3):413-419.
11 Chen WY,Zeng,Carter X,et al.Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors[J].Nat Genet,2003,33(2):197-202.
12 Zheng J,Wang J,Sun X,et al.HIC1 modulates prostate cancer progression by epigenetic modification[J].Clin Cancer Res,2013,19(6):1400-1410.
13 Hao M,Y.Li Y,Wang J,et al.HIC1 loss promotes prostate cancer metastasis by triggering epithelial-mesenchymal transition[J].J Pathol,2017,242(4):409-420.
14 Paget S,Dubuissez M,Dehennaut V,et al.HIC1(hypermethylated in cancer 1)SUMOylation is dispensable for DNA repair but is essential for the apoptotic DNA damage response(DDR)to irreparable DNA double-strand breaks(DSBs)[J].Oncotarget,2017,8(2):2916-2935.
15 Yu J,Liu P,Cui X,et al.Identification of novel subregions of LOH in gastric cancer and analysis of the HIC1 and TOB1 tumor suppressor genes in these subregions[J].MOL CELLS,2011,32(1):47-55.
16 Lánczky A,Nagy Á,Bottai G,et al.miRpower:a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients[J].Breast Cancer Res Treat,2016,160:439-446.
17 Györffy B,Surowiak P,Budczies J,et al.Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer[J].PLoS One,2013,8:e82241.
18 Wang J,Ye C,Lu D,et al.Matrix metalloproteinase-1 expression in breast carcinoma:a marker for unfavorable prognosis[J].Oncotarget,2017,8:91379-91390.
19 Liang YK,Lin HY,Chen CF,et al.Prognostic values of distinct CBX family members in breast cancer[J].Oncotarget,2017,8:92375-92387.
20 Fang E,Zhang X.Identification of breast cancer hub genes and analysis of prognostic values using integrated bioinformatics analysis[J].Cancer Biomark,2017,21(1):373-381.
21 Xie L,Li T,Yang LH.E2F2 induces MCM4,CCNE2 and WHSC1 upregulation in ovarian cancer and predicts poor overall survival[J].Eur Rev Med Pharmacol Sci,2017,21:2150-2156.
22 Zhang X,Wang W,Li P,et al.High TREM2 expression correlates with poor prognosis in gastric cancer[J].Hum Pathol,2018,72:91-99.
23 Xiong J,Zhang X,Chen X,et al.Prognostic roles of mRNA expression of notch receptors in non-small cell lung cancer[J].Oncotarget,2017,8:13157-13165.
24 Huang ZC,Li H,Sun ZQ,et al.Distinct prognostic roles of HSPB1 expression in non-small cell lung cancer[J].Neoplasma,2018,65:161-166.
25 Janeckova L,Kolar M,Svec J,et al.HIC1 expression distinguishes intestinal carcinomas sensitive to chemotherapy[J].Transl Oncol,2016,9:99-107.
26 Rood BR,Zhang H,Weitman DM,et al.Hypermethylation of HIC-1 and 17p allelic loss in medulloblastoma[J].Cancer Res,2002,62(13):3794-3797.
27 Gu XY,Huang XT,Zhang XX,et al.Development and validation of a DNA methylation-related classifier of circulating tumour cells to predict prognosis and to provide a therapeutic strategy in lung adenocarcinoma[J].Int J Biol Sci,2022,18(13):4984-5000.
28 Yanlin W,Zhengjun L,Xianzhe T,et al.Ferroptosis-related gene HIC1 in the prediction of the prognosis and immunotherapeutic efficacy with immunological activity[J].Front Immunol,2023,14:1182030.
29 Yue L,Mengfei Y,Tianqi W,et al.Loss of hypermethylated in cancer 1(HIC1)promotes lung cancer progression[J].Cell Signal,2019,53:162-169.

[1]	徐灵燕, 李倩妮, 李健, 姚雪佩, 刘美娜. 非小细胞肺癌患者首次住院天数对治疗质量的影响分析[J]. 实用肿瘤学杂志, 2024, 38(4): 221-226.
[2]	姚雪佩, 白山奇, 刘美娜. 基于因果图模型的非小细胞肺癌治疗质量影响因素分析[J]. 实用肿瘤学杂志, 2024, 38(4): 227-234.
[3]	李健, 李倩妮, 徐灵燕, 姚雪佩, 刘美娜. 基于双重稳健估计方法的非小细胞肺癌治疗过程对院内死亡的因果效应研究[J]. 实用肿瘤学杂志, 2024, 38(4): 235-240.
[4]	程泳铭, 董欢欢, 徐晖. Hsa-let-7b-5p抑制非小细胞肺癌的增殖、迁移和侵袭[J]. 实用肿瘤学杂志, 2024, 38(3): 157-167.
[5]	张萱, 李欣, 赵康. 血清炎性标志物与一线免疫抑制剂治疗晚期非小细胞肺癌患者预后的关系[J]. 实用肿瘤学杂志, 2024, 38(1): 37-44.
[6]	苗玲, 赵之寒, 王敏. 非小细胞肺癌患者肿瘤组织PA28γ、miR-7-5p的表达水平及临床意义[J]. 实用肿瘤学杂志, 2023, 37(4): 344-350.
[7]	曹莹月, 庞露薏, 张键, 金时. 癌相关成纤维细胞在非小细胞肺癌进展中的作用[J]. 实用肿瘤学杂志, 2023, 37(4): 383-388.
[8]	陈琪, 何明旭, 贾科良, 苗健龙, 韩丽萍. TP53-EGFR共突变对非小细胞肺癌预后及治疗的研究进展[J]. 实用肿瘤学杂志, 2023, 37(3): 262-266.
[9]	龙朝恋, 李琨, 刘子臣, 张娜娜, 车南颖. 非小细胞肺癌程序性死亡配体-1表达与临床病理特征和常见驱动基因变异的相关性研究[J]. 实用肿瘤学杂志, 2023, 37(2): 117-122.
[10]	徐子涵, 于国华, 聂玉辉, 孙蒙蒙, 丰慧, 刘淑真. 外周血标志物对晚期非小细胞肺癌免疫相关不良反应的预测作用及与生存结局的相关性分析[J]. 实用肿瘤学杂志, 2022, 36(6): 544-550.
[11]	朱开彬, 贺长军, 陈澜涛, 孔祥龙, 赵苏, 徐世东. TAM通过PLGF/Flt-1和TGF-β1通路促进非小细胞肺癌生长和肿瘤血管异生的研究[J]. 实用肿瘤学杂志, 2022, 36(5): 391-397.
[12]	刘倩倩, 尚利华. 晚期非小细胞肺癌免疫治疗相关不良反应与疗效的相关性研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 463-467.
[13]	董琳, 刘欣, 鲁海玲. 晚期非小细胞肺癌抗血管生成治疗联合免疫检查点抑制剂的研究进展[J]. 实用肿瘤学杂志, 2022, 36(4): 351-355.
[14]	张浩, 杨新官, 何涌. 肌少症与晚期非小细胞肺癌临床病理特征及预后的相关性分析[J]. 实用肿瘤学杂志, 2022, 36(3): 214-219.
[15]	张艺艺, 李奇, 刘旭, 王亚楠, 邹沅杰, 周慧慧, 徐春燕, 苏升琦, 葛鑫, 王铜. 宫颈癌患者五年生存及影响因素分析[J]. 实用肿瘤学杂志, 2022, 36(1): 7-13.